Gastrointestinal Stromal Tumors - Recent Progress and Upcoming Challenges in a Diverse Disease
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (15 April 2023) | Viewed by 4808
Special Issue Editor
Special Issue Information
Dear Colleagues,
Gastrointestinal Stromal tumors were among the first solid tumors to successfully be treated with tyrosine kinase inhibitors following the identification of KIT and PDGFRA as major oncogenic drivers.
The very recent years have not only added additional drugs as salvage treatments in this subgroup of GIST but also widened the molecular spectrum of non-KIT/non-PDGFRA mutant GIST. Nonetheless, metastatic GIST cannot be cured with current KIT or PDGFRA inhibitors alone.
Our understanding of the heterogeneity of resistance is rapidly improving with the availability of plasma sequencing but further progress will need strong preclinical models to prioritize and validate novel approaches, including combinations and sequences.
This Special Issue aims to focus on the current challenges in both the most common and the rare GIST subtypes. For KIT and PDGFRA mutant GIST, this includes novel mechanisms of resistance and models to recapitulate resistance in vitro. Novel targets and novel drug approaches, tumor dormancy, microenvironment observations of unusual responses, as well as aspects of multimodal approaches involving the most recent new drugs are also of great interest. Clinical cohorts of rare subtypes that help to advise patients particularly with longer follow-up.
We look forward to receiving your contributions.
Prof. Dr. Sebastian Bauer
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gastrointestinal stromal tumor
- actionable mutations
- drug resistance
- tumor heterogeneity
- apoptotic resistance
- tumor dormancy
- prognosis
- tumor-reductive surgery
- complications
- drug development
